# Ironwood Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ironwood-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.ironwoodpharma.com
- Total disclosed funding: $283M
- Latest round: Series I (Nov 17, 2009)
- Investors on record: 17

## About

Ironwood Pharmaceuticals, Inc. specializes in developing and commercializing innovative gastrointestinal treatments, focusing on improving patient care and health outcomes for those with GI diseases.Founded in 1998 and based in Cambridge, US, Ironwood Pharmaceuticals, Inc. concentrates on gastrointestinal healthcare solutions. The firm has made a significant pivot towards focusing on the commercialization of treatments for GI disorders. The company successfully went public in 2010, raising USD 188.00 mn in its IPO and has participated in a total of 9 deals since inception. The CEO, Thomas McCourt, leads the organization, which does not have any noted subsidiaries or parent companies.Ironwood Pharmaceuticals is a prominent player in the gastrointestinal (GI) healthcare sector, dedicated to developing and marketing novel treatments for GI diseases. Its flagship product, LINZESS (linaclotide), launched in 2012, treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). LINZESS enhances fluid secretion in the intestines, promoting bowel movements. Ironwood's offerings cater to healthcare providers, including gastroenterologists and primary care physicians, as well as patients, ensuring effective management of GI disorders across North America and parts of Europe.In the most recent year, 2023, Ironwood Pharmaceuticals generated revenue of USD 442.74 mn. The company's revenue is primarily derived from the sales of prescription medications, particularly LINZESS, through established partnerships with pharmaceutical wholesalers and direct sales to healthcare providers. Despite the revenue generation, Ironwood reported an EBITDA of USD -943.86 mn in 2023, indicating significant operational costs involved in their business.Ironwood Pharmaceuticals is committed to advancing its product pipeline and expanding its market presence. The company is exploring new treatments for digestive health challenges, with plans to launch additional products in the upcoming years. Ironwood aims to penetrate emerging markets in Europe and Asia by 2025 to broaden access to its GI therapies. Recent funding from its IPO will be strategically utilized to support research and development initiatives, enhance marketing efforts, and expand distribution networks, ensuring that innovative treatments reach a wider patient base.

## Funding rounds

- Series I, Nov 17, 2009, $15M — Polaris Partners, Venrock
- Series G, Oct 1, 2008, $50M — Morgan Stanley Investment Management, Invus [DUP], SG Growth Capital, Sigma Capital Partners, Alton, Maverick Capital, Paperboy Ventures, Jennison Associates
- Series F, Feb 1, 2007, $44M — Polaris Partners, Morgan Stanley Investment Management, Venrock, Invus [DUP], SG Growth Capital, Ridgeback Partners, Alton, Maverick Capital, Paperboy Ventures, Jennison Associates, Sigma Capital Management
- Series E, Feb 27, 2006, $75M — Granite Asia, Invus [DUP], SG Growth Capital, Alton, Maverick Capital, Paperboy Ventures, Jennison Associates, Sigma Capital Management
- Series D, May 4, 2004, $40M — Granite Asia, Invus [DUP], SG Growth Capital, Alton, Paperboy Ventures
- Series C, Apr 1, 2002, $26M — BancBoston Capital - PEP, Polaris Partners, Aberdare Ventures, Venrock, F-Prime Capital, Essex Investment Management
- Series B, Nov 1, 2000, $23M — BancBoston Capital - PEP, Polaris Partners, Aberdare Ventures, Venrock, Essex Investment Management
- Series A, Apr 1, 1999, $9.8M — Polaris Partners, Venrock

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series F, Series I
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B, Series C, Series F, Series I
- BancBoston Capital - PEP (https://capitalatlas.ai/funds/bancboston-capital-pep) — Series B, Series C
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series B, Series C
- Essex Investment Management — Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series C
- Granite Asia (https://capitalatlas.ai/funds/granite-asia) — Series D, Series E
- Invus [DUP] — Series D, Series E, Series F, Series G
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series D, Series E, Series F, Series G
- Alton — Series D, Series E, Series F, Series G
- Paperboy Ventures (https://capitalatlas.ai/funds/paperboy-ventures) — Series D, Series E, Series F, Series G
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series E, Series F, Series G
- Jennison Associates — Series E, Series F, Series G
- Sigma Capital Management — Series E, Series F
- Morgan Stanley Investment Management — Series F, Series G
- Ridgeback Partners — Series F
- Sigma Capital Partners (https://capitalatlas.ai/funds/sigma-capital-partners) — Series G